Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.55
$0.06(4.28%)
At close: 4:00 PM EDT
$1.55
$0.06(4.28%)
Day’s Range― - ―
52-Week Range$0.65 - $5.93
Previous Close$1.61
Volume1.23M
Average Volume (3M)1.58M
Market Cap
$40.12M
Enterprise Value$83.54M
Total Cash (Recent Filing)$45.09M
Total Debt (Recent Filing)$143.45K
Price to Earnings (P/E)―
Beta3.08
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume2,583,361
30 Day Avg. Volume1,581,160
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap2.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.25K
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$2.00Price Target Upside29.03% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Regulatory Engagement And Pipeline PotentialThe company is actively pursuing FDA review of reproxalap rather than abandoning its lead ophthalmology program. Its submission cites nine adequate and well-controlled trials, including five meeting multiplicity-controlled endpoints, preserving a potential regulatory pathway and commercial opportunity.
Extended Cash RunwayA projected operational cash runway into 2029 gives Aldeyra additional time to pursue regulatory engagement, develop its pipeline, and potentially resubmit reproxalap. This reduces immediate financing pressure and supports continuity through a multi-quarter development process.
Manageable Annual LeverageModest annual debt relative to equity indicates that Aldeyra has not relied heavily on borrowing to fund its operations. Lower leverage can preserve financial flexibility and limit interest-related pressure while the company works toward regulatory approval and future revenue generation.
Bears Say
No Demonstrated Revenue BaseAldeyra has not yet demonstrated commercial revenue generation, leaving its business model dependent on successful clinical development and regulatory approval. Without product sales, the company lacks internally funded growth and remains exposed to extended development timelines.
Persistent And Worsening Cash BurnPersistent negative operating and free cash flow means Aldeyra is funding operations externally rather than through its business. The sharp TTM deterioration versus 2025 signals renewed spending intensity, which can increase financing needs before sustainable revenue is established.
FDA Approval SetbackThe Complete Response Letter shows that Aldeyra’s lead candidate has not secured approval despite its clinical evidence. The planned dispute process has uncertain timing and outcome, creating regulatory risk that could delay commercialization and prolong the company’s pre-revenue period.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $0.65 and its highest was $5.93 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $40.12M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 06, 2027 which is in 196 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.09 earnings per share for the quarter.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,326,420 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.09 in its last earnings report. Following the earnings report the stock price went down -3.75%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (29.03% Upside)
$2.00 (29.03% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.50%
12-Months-Change
Fundamentals
Return on Equity
-53.14%
Trailing 12-Months
Asset Growth
-44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$2.00
▲(29.03% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.29% Insiders
8.73% Mutual Funds
0.45% Other Institutional Investors
82.44% Public Companies and
Individual Investors